Blindness Disease Articles & Analysis
10 news found
” About Retinitis Pigmentosa Retinitis pigmentosa (RP), is a heterogeneous group of genetic diseases that cause retinal degeneration leading to near or complete blindness for most patients. The severe loss of photoreceptor cells that occurs in this genetic degenerative disease leads to partial or complete blindness. At ...
With a 26.8% prevalence of diabetes for people over the age of 65, there are 14.3 million seniors alone who are at risk of developing visual loss or blindness. Diabetic eye diseases are treatable, and blindness can be prevented for most patients with early detection and treatment. ...
We are excited for rapid expansion in the region and are impressed with the Kingdom’s speed in adopting artificial intelligence to prevent blindness in its country.” The Saudi Arabian population has one of the most acute needs for a diagnostic technology like IDx-DR. ...
“Although protection against severe disease remains high six months following the second dose, a decline in efficacy against symptomatic disease over time and the continued emergence of variants are expected and consistent with what we are seeing with other vaccines. ...
Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen’s pediatric Emergency Use Authorization (EUA) submission in the United States for children 2-18 on November 5, 2021. ...
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and ...
(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, announced that the U.S. ...
As recently published in, The Lancet, COVAXIN™ (BBV152) demonstrated 77.8% overall efficacy, 63.6% efficacy against asymptomatic disease and 65.2% efficacy against the Delta variant in the Phase 3 clinical trial of nearly 25,800 participants. ...
MEEI is home to the medical school's Department of Ophthalmology Ocular Genomics Institute, which is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases. "Becoming an Agilent CSP enables us to provide the ocular genomics research community with access to the latest protocols and technologies ...
The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection. Recognized by the World Health Organization (WHO) as a neglected tropical disease, Chagas ...